| Title: | Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : updated analysis of the observational GioTag study |
|---|
| Authors: | ID Hochmair, Maximilian J (Author)
ID Morabito, Alessandro (Author)
ID Hao, Desiree (Author)
ID Yang, Cheng-Ta (Author)
ID Soo, Ross A (Author)
ID Yang, James C-H (Author)
ID Gucalp, Rasim (Author)
ID Halmos, Balazs (Author)
ID Wang, Lara (Author)
ID Märten, Angela (Author)
ID Čufer, Tanja, Klinika Golnik, Medicinska fakulteta UL (Author) |
|---|
| Files: |  PDF - Presentation file, download (1,58 MB)
MD5: AE826F62EC54CB83F71667FE803EEB71
PDF - Supplement, download (1,10 MB)
MD5: 501E9A968487DEB2D03082EAB847B278
 URL - Source URL, visit https://www.futuremedicine.com/doi/full/10.2217/fon-2019-0346
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
|
|---|
| Abstract: | Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. |
|---|
| Keywords: | non-small cell lung carcinoma - therapy, drug therapy, afatinib, osimertinib, GioTag study |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Place of publishing: | Velika Britanija |
|---|
| Publisher: | Future Medicine Ltd |
|---|
| Year of publishing: | 2019 |
|---|
| Number of pages: | str. 2905-2914 |
|---|
| Numbering: | Vol. 15, iss. 25 |
|---|
| PID: | 20.500.12556/DiRROS-12417  |
|---|
| UDC: | 616.2 |
|---|
| ISSN on article: | 1744-8301 |
|---|
| DOI: | 10.2217/fon-2019-0346 |
|---|
| COBISS.SI-ID: | 2048610929 |
|---|
| Copyright: | © 2019 Maximilian J Hochmair |
|---|
| Note: | Nasl. z nasl. zaslona;
Soavtorica iz Slovenije: Tanja Cufer;
Opis vira z dne 10. 1. 2020;
|
|---|
| Publication date in DiRROS: | 11.09.2020 |
|---|
| Views: | 1812 |
|---|
| Downloads: | 1368 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
